A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...

詳細記述

書誌詳細

出版年:	Pharmaceuticals
主要な著者:	Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2023-04-01
主題:	age-related macular degeneration polypoidal choroidal vasculopathy intravitreal brolucizumab injection treat-and-extend switching
オンライン･アクセス:	https://www.mdpi.com/1424-8247/16/4/562